
Purpose: To investigate posterior vitreous detachment (PVD) status in eyes with branch retinal vein occlusion (BRVO) and its relationship to structural and treatment outcomes. Methods: Retrospective cohort study of eyes with treatment-naïve BRVO diagnosed within one year of onset from 2009 through 2021, with at least one year of follow-up. Eyes were stratified by PVD status on optical coherence tomography at presentation. Outcomes included cystoid macular edema (CME) prevalence, central subfield thickness (CST), and number of intravitreal injections. Results: Of 88 eyes, 33 (37.5%) had complete PVD and 55 (62.5%) did not. Patients with complete PVD were older (median 75 vs 67 years; p=0.02) and had a lower prevalence of hypertension (66.7% vs 89.1%; p=0.01). At one year, CME was less frequent in eyes with complete PVD (65.6% vs 88.9%; p=0.01), after adjustments for hypertension, baseline CME, and CST. Eyes with complete PVD had lower median CST (277.5 vs 301.0 μm; p=0.045) and required fewer median injections (4.0 vs 7.0; p=0.01) at one year, after adjustments for baseline CME and CST, but not hypertension. A significant interaction between baseline CST and PVD status was observed for one-year injection burden (p=0.03), with complete PVD associated with fewer injections at lower CST, but more injections at higher CST. Conclusion: In eyes with BRVO, complete PVD at presentation was associated with lower one-year CME prevalence, CST, and injection burden. The relationship between PVD status and injection burden varied by baseline CST, suggesting PVD status and CST may provide complementary information regarding treatment burden.
Purpose: To report the incidence, clinical characteristics, and visual and anatomical outcomes of rhegmatogenous retinal detachment (RRD) following pars plana vitrectomy (PPV) for symptomatic vitreous floaters. Methods: This retrospective, consecutive case series evaluated 256 eyes of 205 patients who underwent PPV for symptomatic floaters with a minimum 6-month follow-up. Main outcomes included RRD incidence, single surgery anatomical success, final reattachment rates, and visual acuity (VA) changes. Results: Over a mean follow-up of 31.8 months, 14 of 256 eyes (5.5%) developed an RRD at a median of 19 days postoperatively. At presentation, 78.6% of detachments were macula-on. Final anatomical success was achieved in 100% of eyes with all successfully maintaining reattachment without the need for long-term silicone oil. Among eyes that developed RRD, median logMAR visual acuity changed from 0.00 (20/20) preoperatively to 0.18 (20/30) at the final visit, though this did not reach statistical significance (P=0.084). Ultimately, 3 of the 14 RRD eyes (21.4%), representing 1.2% of the total surgical cohort, lost 3 or more lines of vision compared to baseline. Conclusion: PPV for symptomatic floaters is associated with a small risk of postoperative RRD. All eyes were successfully reattached with 1.2% experiencing a loss of 3 or more lines of vision
Purpose: To investigate the real-world incidence and management of ocular hypertension (OHT) following the intravitreal 0.19 mg fluocinolone acetonide implant (FAi, Iluvien) for diabetic macular edema (DME). Methods: Retrospective review of eyes treated with FAi (2015-2025) with ≥1 month follow-up. Primary outcome was OHT (IOP >25 mmHg). Secondary outcomes included IOP >30 mmHg, IOP rise ≥10 mmHg from baseline, and OHT management. Results: A total of 118 eyes (90 patients) were included with mean follow-up of 33.1 ± 1.3 months. Mean baseline IOP was 14.0 ± 3.0 mmHg. Pre-existing glaucoma or OHT was present in 32.2% of eyes, and 78.8% had a prior periocular or intravitreal corticosteroid injection. Overall, 11 eyes (9.3%) developed OHT (IOP >25mmHg) following FAi. Peak IOP >30 mmHg occurred in 6 eyes (5.1%), and 12 eyes (10.2%) had an IOP rise ≥10 mmHg above baseline. OHT developed at variable time points, with 36.4% of cases occurring between 6-12 months and 27.3% after 24 months; mean time to OHT development was 15.6 ± 13.1 months. Higher baseline IOP was associated with increased odds of developing OHT (OR per 1mmHg increase 1.32, p=0.02). Of the 11 eyes with OHT, most were managed medically (63.6%) or with observation (36.4%) alone, with only 1 eye (9.1%, 0.8% of entire cohort) requiring incisional glaucoma surgery. Conclusion: FAi was associated with low rates of OHT, with most cases managed with observation or topical therapy, with surgery rarely required. This supports the safety of FAi and highlight the importance of extended IOP monitoring.
Purpose: To characterize vitreoretinal architecture in peripheral degenerative retinoschisis using high-resolution swept-source optical coherence tomography and to distinguish two morphologically and potentially mechanistically distinct forms of retinoschisis.Methods: This retrospective imaging study evaluated eyes with peripheral degenerative retinoschisis using swept-source optical coherence tomography with extended dynamic-range processing and volume rendering. Retinoschisis was categorized as columnar retinoschisis, with residual intraretinal tissue columns, or bullous retinoschisis, with a large intraretinal cavity. Anatomical features were assessed descriptively and interpreted in the context of retinal physiology.Results: Nineteen eyes of 11 patients were analyzed. All eyes demonstrated regions of columnar retinoschisis, and 13 eyes also showed bullous retinoschisis. Vitreoschisis was identified only in eyes with bullous retinoschisis. Imaging commonly showed adherent cortical vitreous overlying schitic regions, with adjacent vitreous liquefaction, a configuration inconsistent with sustained traction as the sole explanation for the schisis cavity. Columnar retinoschisis was associated with limited separation between retinal layers and was typically contiguous with bullous schisis, which showed substantially greater intraretinal cavity height.Conclusion: These findings support the distinction between columnar and bullous retinoschisis as separate morphologic entities. Although vitreous traction may contribute to initiation of retinoschisis, progression to bullous schisis may involve additional mechanisms. Loss of M & uuml;ller cell columns may remove both a structural element that limits expansion of the schisis cavity and a pathway for intraretinal fluid regulation through the deep capillary plexus, allowing metabolic water production to contribute to cavity enlargement in the absence of sustained mechanical forces.
Purpose: To describe two recurrent phenotypes of retinal pigment epithelium (RPE) defects, sealed and unsealed, which may occur in various diseases.Methods: Medical records and multimodal imaging of 17 patients (70.3 +/- 9.3 years) with RPE defects, including RPE apertures, RPE detachment (retinal pigment epithelium detachment) devoid of RPE, and serous maculopathy with the absence of RPE, were retrospectively analyzed. Proposed pathogenic mechanisms are presented, revising current terminology.Results: Eyes with RPE apertures (12/17, 70.6%) and serous maculopathy with the absence of RPE (1/17, 5.9%) presented RPE defects connecting the subretinal and sub-RPE spaces with subretinal fluid (SRF) and intact outer retina. These features are consistent with patent RPE defects, termed "unsealed." Retinal pigment epithelium detachment devoid of RPE defects developed in & frac34; eyes (75%) over a serous PED without collapse. The lesions occurred beneath a degenerated outer retina that adheres to the RPE defect without SRF, supporting the term "sealed."Conclusion: RPE defects beneath a disrupted photoreceptor layer may become "sealed" by reactive M & uuml;ller cell gliosis, preventing the occurrence of SRF. Retinal pigment epithelium defects with intact photoreceptors remain "unsealed," resulting in SRF accumulation. We propose "sealed" and "unsealed" as disease agnostic terms, which can be used for cases previously described as "RPE aperture," "serous maculopathy with the absence of RPE," and "RPED devoid of RPE."